Home Clinical Beyond dire wolves: Could Colossal’s de-extinction work transform human health?

Beyond dire wolves: Could Colossal’s de-extinction work transform human health?

by Newsroom


When CEO Ben Lamm steps into the spotlight, it’s usually to talk about his efforts bringing extinct animals back to life. Once a far-flung idea, Lamm and the company he heads, Colossal Biosciences, have proven they can pull it off.

That wow-inducing moment came last year when Colossal unveiled “dire wolf” pups created with gene engineering techniques that leveraged a rewritten genome made from preserved DNA. 

Born with 20 dire wolf traits, the modified gray wolves now boast large, muscular frames, sharper teeth and a distinctive howl that’s been absent from earth for over 10,000 years. But the fair-haired canines are just the tip of what Lamm and Colossal hope to achieve.

Similar to the way NASA’s effort to launch humans into space once triggered a frenzy of technological advances in areas like energy production and materials science, Colossal bills its…



Source link

You may also like

About Us

Pharma Newswire™ aggregates, publishes and distributes news in the Pharmaceutical Industry. In association with EmailWire, Pharma Newswire™ provides press release distribution services in the pharmaceutical sector. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. To send a press release, contact us through the following messaging apps:

Pharma Newswire™ is part of GroupWeb Media Network. © 2025 GroupWeb Media LLC